A Belgian startup, NeuroClues, is aiming to revolutionize the diagnosis of neurodegenerative diseases like Parkinson's with a ten-minute, objective test—a bold claim in a field still heavily reliant on clinical observation and practitioner experience.

The company is developing a medical device that converts complex biological signals into measurable, exploitable data. The core of its approach involves tracking and analyzing microscopic, involuntary eye movements, known as microsaccades. These movements are controlled by brain structures deeply affected by Parkinson's disease, such as the basal ganglia and the superior colliculus.

By using a specialized camera to record these eye movements at high speed, NeuroClues's software creates a unique "oculomotor fingerprint" for each patient. Advanced algorithms then compare this fingerprint against a database to detect anomalies indicative of Parkinson's or other conditions. The goal is to provide a rapid, quantitative, and accessible diagnostic tool that could enable earlier intervention.

This technology represents a significant shift toward data-driven neurology. If successful, it could address a major diagnostic bottleneck, offering a less subjective and potentially more scalable alternative to current methods that depend on specialist evaluation and often occur only after significant symptom progression.

Diagnostiquer une maladie neurodégénérative en dix minutes. L’énoncé tient presque de la provocation, dans un domaine où le diagnostic reste encore largement fondé sur l’observation clinique et l’expérience du praticien. Avec cette promesse, NeuroClues s’inscrit dans une médecine qui tente de convertir des signaux biologiques complexes en données mesurables, et exploitables. Un diagnostic qui arrive …

L’article Dix minutes pour diagnostiquer Parkinson ? le pari de NEUROCLUES est apparu en premier sur FW.MEDIA.